Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease

Movement Disorders

Volumn 20, Issue 8, 2005, Pages 932-936

  Bara Jimenez, William ^a   Bibbiani, Francesco ^a   Morris, Michael J ^a   Dimitrova, Tzvetelina ^a   Sherzai, Abdullah ^a   Mouradian, Maral M ^a   Chase, Thomas N ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

5 HT1A receptor; Dopamine; Dyskinesias; Levodopa; Parkinson's disease; Serotonin; Striatum

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SARIZOTAN; SEROTONIN 1A AGONIST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSKINESIA; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MALE; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANIC CHEMICALS; PARKINSON DISEASE; RECEPTOR, SEROTONIN, 5-HT1A; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 26444586231     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20370     Document Type: Article

References (32)

1. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000; 47(Suppl.):122-129.
2. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55:72-77.
3. Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
4. Hadj Tahar A, Gregoire L, Bangassoro E, Bedard PJ. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 2000;23:195-202.
5. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 2000;247(Suppl.):1143-1150.
6. Winkler C, Kirik D, Bjorklund A, Cenci MA. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002;10:165-186.
7. Lin JY, Dubey R, Funk GD, Lipski J. Receptor subtype-specific modulation by dopamine of glutamatergic responses in striatal medium spiny neurons. Brain Res 2003;959:251-262.
8. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6:501-506.
9. Marino M, Valenti O, Conn PJ. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging 2003; 20:377-397.
10. Arai R, Karasawa N, Nagatsu I. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 1996;706: 177-199.
11. Tanaka H, Kannari K, Maeda T, et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999;10:631-634.
12. Kannari K, Yamato H, Shen H, et al. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001;76: 1346-1353.
13. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-1152.
14. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiporkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002;303:815-822.
15. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991;43:587-604.
16. Bibbiani F, Oh JD, Chase TN, Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology, 2001;57:1829-1834.
17. Rabiner EA, Gunn RN, Wilkins MR, et al. Evaluation of EMD 128130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol 2002;16:195-199.
18. Russ H. EMR 62225: Sarizotan/Investigator's Brochure. Merck KGaA, Darmstadt, Germany; 2002.
19. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
20. Hammerstad JP, Carter J, Nutt JG, et al. Buspirone in Parkinson's disease. Clin Neuropharmacol 1986;9:556-560.
21. Bonifati V, Fabrizio E, Cipriani R, et al. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82.
22. Durif F, Vidailhet M, Assal F, et al. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997;48:658-662.
23. Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTP-γS binding study. Eur J Pharmacol 1998;355:245-256.
24. Gobert A, Lejeune F, Rivet JM, et al. Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. J Pharmacol Exp Ther 1995;273:1032-1046.
25. Nomikos GG, Arborelius L, Hook BB, et al. The 5-HT1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum. J Neural Transm 1996;103:541-554.
26. Santiago M, Matarredona ER, Machado A, Cano J. Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J Neurosci Res 1998;52:591-598.
27. Ichikawa, J, Meltzer HY. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 2000;858:252-263.
28. Hadj Tahar A, Belanger N, Bangassoro E, et al. Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys. Eur J Pharmacol 2000;399:183-186.
29. Lucas G, Bonhomme N, De Deurwaerdere P, et al. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 1997;131:57-63.
30. Henderson J, Yiannikas C, Graham JS. Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinsoh's disease. Clin Exp Neurol 1992;29:277-282.
31. Oh JD, Bibbiani F, Chase TN. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 2002;177:557-564.
32. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.